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ABSTRACT The internal motions of proteins may serve as a ‘‘gate’’ in some systems, which controls ligand-protein asso-
ciation. This study applies Brownian dynamics simulations in a coarse-grained model to study the gated association rate con-
stants of HIV-1 proteases and drugs. The computed gated association rate constants of three protease mutants, G48V/V82A/
I84V/L90M, G48V, and L90M with three drugs, amprenavir, indinavir, and saquinavir, yield good agreements with experiments.
The work shows that the ﬂap dynamics leads to ‘‘slow gating’’. The simulations suggest that the ﬂap ﬂexibility and the opening
frequency of the wild-type, the G48V and L90M mutants are similar, but the ﬂaps of the variant G48V/V82A/I84V/L90M open
less frequently, resulting in a lower gated rate constant. The developed methodology is fast and provides an efﬁcient way to
predict the gated association rate constants for various protease mutants and ligands.
INTRODUCTION
The important ﬁrst step in many biological processes is the
encounter of protein-protein or protein-ligand molecules. For
example, in the system of human immunodeﬁciency virus
type 1 (HIV-1), the viral polyprotein has to bind to the active
site of the HIV-1 protease to produce active structural and
replicative proteins (1). HIV-1 protease drugs also have to
associate with the protease and typically compete with the
polyprotein binding. The binding beginswith the encounter of
the two molecules by random walks, and the association
presumably occurs at a rate that approaches the diffusion-
controlled limit (2–4). However, in theHIV-1 protease system
mentioned above, the experimentally measured association
rate constant is a few orders of magnitude smaller than that
expected if the molecules were uniformly reactive spheres
(5,6). Deviation of this limiting rate may result from geo-
metric constraints of the binding sites, interaction potentials,
hydrodynamic interactions, and the binding site accessibility
due to protein internal motions (7–11). Strong electrostatic
steering may enhance the rate of association, and the require-
ment of high steric speciﬁcity of both molecules may reduce
the association rate (3,12). In some cases, the association rate
constants may be further lowered by the dynamic nature of
a protein, which modulates the binding site accessibility and
can be viewed as a ‘‘gated’’ binding site (13,14).
A number of experimental works show that some enzymes
have loops over their active sites whose conformational
changes can ‘‘gate’’ ligand binding (15–17). For example, the
active site loop of triosephosphate isomerase (TIM) exhibits a
hinged-lid motion, which alternates between the two well-
deﬁned open and closed conformations (18). The ﬂuctuations
of the protein chain of myoglobin serve as a gate that opens
and closes the reaction binding site, and permit small ligands
(O2 andCO) to enter the heme ‘‘pocket’’ (19,20). The concept
of gating has been applied to study association rate constants
coupled to conformational changes in the active sites of
enzymes, both in equilibrium and out of equilibrium (21–26).
Earlier theoretical works use the kinetics schemes of gate
opening and closing, together with the characteristic diffu-
sional relaxation time of the ligand-protein system, to estimate
gated association rate constants (14). Computer simulations
have also been applied directly to estimate the gating effects
on protein-ligand association, i.e., with explicit modeling of
the gate motion (27,28), though such studies are challenging
due to the limited conﬁgurational sampling that is possible
with typical simulation techniques.
This study focuses on the ﬂuctuations of HIV-1 protease
ﬂaps, which modulate the binding site accessibility. We
studied wild-type protease and three mutants, G48V/V82A/
I84V/L90M, L90M, and G48V with three clinically used
drugs, amprenavir, indinavir, and saquinavir, where experi-
mental data are available (29). The work uses a coarse-
grained model to simulate substantial protein conformational
changes (30), and Brownian dynamics to perform microsec-
ond (ms) timescale simulations (31,32). The use of a ﬂexible
force ﬁeld allows study of the opening/closing of the ﬂaps of
the active site. Applying such a ﬂexible force ﬁeld is nec-
essary, as simpler Go-like models cannot describe the com-
plicated ﬂap dynamics (30). The computed association rate
constants of HIV-1 variants yield good agreements with
experimental values.
Theoretical background
To estimate the effects on the association due to the ﬂap
motions, we assume that the protein has two conformational
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states: open and closed. The opening and closing of a gate
modulates the accessibility of a binding site of the protein,
and may be described as
open E*
kc
ko
closed; (1)
where ko and kc are rate constants of gate opening and
closing, respectively. For systems which have such a gating
effect on ligand binding, the gated association rate constant
kG is given by (14)
1
kG
¼ 1
kUG
1
kc
ko  ðko1 kcÞ  k^uðko1 kcÞ; (2)
where k^u(k) is the Laplace transform of the time-dependent
rate constant of the ungated protein, a quantity deﬁned for
the ungated situation (the binding site is completely open and
accessible by a ligand), and kUG is the steady-state rate
constant for the ungated protein. Based on the characteristic
diffusional relaxation time td of the ligand-protein system, it
may be a slow or fast gating system. In these cases, Eq. 2
may be further rewritten as (13,14,26,33):
kG ¼ kUG ko
kc1 ko
; ðkc1 koÞ1  td (3)
kG ¼ kUG; ðkc1 koÞ1  td (4)
td ¼ r2c=D; (5)
where rc is the collision distance between the molecules and
D is their relative translational diffusion constant. We call it
‘‘slow gating’’ if the opening and closing of the gate is slow
compared to the characteristic time for diffusion td (see Eq.
3). The association rate constant is then simply the steady-
state association rate constant for the ungated reaction kUG
multiplied the probability that the gate is open. If the gate
ﬂuctuation is fast compared to td as shown in Eq. 4, it ap-
pears to the ligand that the binding site is always open.
For a diffusion controlled reaction between uniformly
reactive spheres with the absorbing boundary condition,
kUG ¼ kD ¼ 4p rc D. If ligand-protein interactions U(r)
are centrosymmetric when r . rc, an analytical expression
for kUG can be written as
kUG ¼ 4p
Z N
rc
exp½UðrÞ=kT
r
2
D
dr
 1
: (6)
However, if the ligand-protein interactions include real-
istic descriptions of the irregular surface topography and the
molecular interactions, the above equation is not accurate,
and one must rely on computer simulations, as described in
previous publications (7,34–36).
Simulation methods
Coarse-grained model of HIV-1 protease
A coarse-grained model is used here to represent HIV-
1 protease, and has been implemented into the University of
Houston Brownian Dynamics (UHBD) simulation package
(37). Each amino acid is represented by a single interaction
center (bead), and an effective residue radius (ri) is assigned
to each bead (38–42). The center of each bead is placed on
the alpha carbon, and 6 1e charge is assigned to a charged
residue. These centers are linked by virtual bonds, bond
angles, and dihedral angles for consecutive residues. A coarse-
grained force ﬁeld for HIV-1 protease, previously developed
by Tozzini and McCammon (30), was extended to include the
solvent effects, via screened electrostatics and Brownian
dynamics. The effective residue radius of each bead was taken
from a previous publication of Reva et al. (43). The potential
energy function is a sum of ﬁve kinds of interactions:
U ¼ Ubond1Uangle1Udihe1Uvdw1Uelec: (7)
The bond and dihedral interactions are harmonic, and the
angle term is in the quartic form:
Ubond ¼ +kbðb b0Þ2 (8)
Uangle ¼ +1
2
kuðu u0Þ21 1
3
k9uðu u0Þ31 1
4
ku$ðu u0Þ4 (9)
Udihe ¼ +kfðf f0Þ2; (10)
where kb ¼ 70 kcal/mol/A˚2, ku ¼ 38 kcal/mol/rad2, kf ¼ 5
kcal/mol/rad2, b0 ¼ 3.8 A˚, and u0 ¼ 90 (30). The other
parameters, k9u, ku$, and f0 are computed based on a ref-
erence structure, Protein Data Bank code 1hhp in this study
(44), and are amino-acid speciﬁc.
For nonbonded interactions (two beads not connected by a
virtual bond, bond angle, or dihedral angle), a cutoff is set to
be 15 A˚ for intramolecular interaction. The Coulombic inter-
action between each pair of beads i and j is Uelec ¼ qiqj/erij
and Uvdw is
Uvdw¼
(
e½ð1eaðrijr0ÞÞ21 for rij# 8:0A˚
0:20708½ð1e0:70711ðrij9:75ÞÞ21 for 8, rij#15A˚
;
(11)
where Uvdw is the intramolecular van der Waals interaction,
and e and a are parameters deﬁned from the force ﬁeld. Also,
rij is the distance between beads i and j, and r0 is the equi-
librium distance taken from a reference conformation. No
detailed solvent model was used, but a distance dependent
dielectric constant (eij¼ 4rij) was used to avoid unrealistic in
vacuo Coulombic interactions.
Brownian dynamics approach
The detailed derivation of the Brownian dynamics simulation
algorithm used here was reported in a previous publication
(31). Please note that the use of Brownian dynamics is crucial
since it provides appropriate timescales to compute Eqs. 3–5
for determining the gating effects. In this algorithm, we solve
the Langevin equation of internal motion in the overdamped
limit, and the resulting equation gives a Brownian trajectory:
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dri ¼ Di
kBT
f idt1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2Didt
p
Ri; (12)
where Di is the diffusion coefﬁcient of bead i, kB is the
Boltzmann constant, and T is the absolute temperature. The
systematic force on each bead fi is the negative gradient of
the potential energy given above, fi ¼ =U(ri), and Ri is a
random displacement due to the collision with the solvent.
During the simulation, the time step dt is set to 0.1 ps.
The diffusion coefﬁcient Di of bead i was computed by
Di ¼ kBT
6phðri1 1:4 A˚Þ
:
This is essentially the Stokes-Einstein equation, and the hy-
drodynamic radius is approximated by the effective radius of
each bead, ri, plus the water radius, 1.4 A˚, used in this study
(31,32). The viscosity of water h is 1 cp (T ¼ 293 K).
RESULTS AND DISCUSSION
HIV-1 protease internal motion
The motions of the wild-type enzyme and three variants of
HIV-1 protease (G48V, L90M, and G48V/V82A/I84V/
L90M) were studied (Fig. 1). The ﬂaps of the wild-type
protease and mutants sample completely open and closed
conformations in the Brownian dynamics simulations, as
detailed in a previous publication (30); such conformations
are shown in Fig. 2. The open/closed conformations of the
mutants are similar to those found in the wild-type protease,
but the average time of the open fractions are not all the
same. The opening events have no signiﬁcant difference
between the wild-type and both L90M and G48V mutants,
and all have ;14% open conformations in a 20-ms simu-
lation. Note that no experimental data reported the fraction of
time that the ﬂaps are open/closed. However, in the wild-type
protease, the fraction of open conformations is consistent
with the value reported recently by all-atom molecular
dynamics simulations (45). In contrast, it is harder for the
G48V/V82A/I84V/L90M mutant to open, and only ;2%
conformations are in an open form. Although such a coarse-
grained model cannot accurately represent the detailed
atomic interactions, it still can provide the overall structure
and ﬂexibility of the protein with less speciﬁc side-chain inter-
actions, e.g., hydrophobic interactions and steric clashes. The
substitution of Leu-90 by Met has little effect on the protein
internal motion, presumably because residue 90 does not
directly interact with the ﬂaps. Interestingly, although the
G48V substitution is in the ﬂap region, the change does not
cause signiﬁcant difference in the protein dynamics. Simul-
taneous substitution of G48V,V82A, I84V, and L90M causes
more signiﬁcant changes of the intramolecular interactions,
resulting in more rigid ﬂaps. The ﬂap-tip distance versus
simulation time of the wild-type protease and the G48V/
V82A/I84V/L90M mutant is illustrated in Fig. 3. The ﬂaps
of the mutant open less frequently and the opening time is
also shorter. In the wild-type protease, G48V and L90M
mutants, the average ﬂap open and closed times are;70 and
430 ns, respectively, but the average open time drops by half
to ;35 ns in G48V/V82A/I84V/L90M mutant. We can
calculate the opening and closing rate constants from these
simulations. For example, the rate constants ko and kc of the
wild type protease may be estimated by 1/430 and 1/70 ns1,
respectively.
Gated rate constant
Based on the computed rate constants, the ﬂap motions may
be viewed as ‘‘slow gating’’, as described by Eq. 3. Our sim-
ulations yield (kc 1 ko)
1  60 ns. This is much larger than
the diffusional relaxation time if we assume that binding will
occur when rc ¼ 20 A˚ and the protein and ligand have
approximate radii of 30 A˚ and 8 A˚, respectively. As a result,
the gated association rate constant may be estimated by the
ungated rate constant multiplied by the opening probability,
FIGURE 1 Representation of the HIV-1 protease in the coarse-grained
model. Each bead represents a residue and the mutated residues are marked
by enlarged spheres.
FIGURE 2 Open (black) and closed (gray) conformation of the wild-type
HIV-1 protease from the coarse-grained model.
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ko/(ko 1 kc). For HIV protease 1 substrate, the experimen-
tally measured kG ranges from 10
4 to 106 M1s1 (5,46), so
if the ﬂaps are always open, the association rate may be
approximated roughly as 105 to 107 M1s1. The association
rate still is smaller than the diffusion limit for uniformly
reactive spheres, ;1010 M1s1, estimated from the size of
both molecules. As described earlier, this difference is of the
expected size, given that successful complex formation hinges
on a proper orientation and conformation of both the sub-
strate and the protein (7). Since the charges of mutated
residues do not change, the change of the association rate
caused by electrostatic effect is less signiﬁcant. As a result, it
is the ﬂap dynamics that may determine most of the changes
of the association rate constant due to the mutations con-
sidered here. The ﬂap motion in mutants G48V and L90M is
very similar to that in the wild-type, so the gated association
rate measured from a substrate binding to the mutant may
remain nearly the same. Unlike the G48V and L90Mvariants,
G48V/V82A/I84V/L90M mutant shows less ﬂexible ﬂap
motions, so a decrease of a few fold in kG may be estimated,
as the opening probability is only 2%.
Because experimentally measured association rates of the
binding between a substrate and HIV-1 protease variants are
not available, the kinetics data of clinically used drugs and
protease mutants are considered here. Table 1 lists experi-
mental association rate constants of the proteases and three
clinically used protease drugs, amprenavir, indinavir, and
saquinavir. Note that different experimental methods may
result slightly different kinetics constants. For an easier com-
parison, we used a data set obtained from the same assay
method for all of the HIV drugs (29). It has been suggested
that these peptidomimetic drugs have similar binding modes
to the substrate, but the drugs are smaller as shown in Fig. 4
(47). Based on the assumption that the ﬂaps of the protease
have to be in an open conformation to allow ligand access,
we estimate that kG for the binding of drugs to the wild-type
and variants G48V and L90M proteases will be similar. In
contrast, the association rate for drugs binding to the G48V/
V82A/I84V/L90M mutant may decrease up to sevenfold,
since the ﬂaps are only open ;2% of the time, compared
to ;14% open fraction in the wild-type protease.
The computed association rates are listed in Table 1. For
example, the estimated value of kG of saquinavir to enzyme
with substitutions at G48V/V82A/I84V/L90M is ;1.5 3
105 M1s1. The kG of saquinavir to enzyme with substi-
tution at G48V and L90M are both ;1 3 106 M1s1. Our
estimation successfully predicts the trend of the change of
association rate constants, but the approximated kG is up to
twofold lower than those determined in experiments for
drugs binding to the G48V/V82A/I84V/L90Mmutant. Given
the approximations in our coarse-grained model, the level of
agreement seems surprisingly good. Some errors may result
from the absence of complicated drug-protein interactions
and/or from our deﬁnition of an open form. For example, we
deﬁne open conformations when the ﬂap tip distances are
.15 A˚, but the ﬂaps also ﬂuctuate when the tip distances are
;15 A˚. Thus a drug may be able to access the binding site
for some conformations which are counted as ‘‘closed form’’
in our simulations, and a real population of the open form
may be larger than what we obtained here. Moreover, unlike
substrates that have an extended structure, the drugs shown
here are smaller and they may not need a fully open con-
formation to bind to the enzyme, yielding a larger kG.
CONCLUSIONS
This article uses Brownian dynamics simulations of a coarse-
grained model to study the gated association rate constants in
HIV-1 proteases. The simulations showed that in the wild-
type and variants G48V and L90M proteases, the ﬂaps open
;14% of the time, and the opening fraction drops to 2% in
mutant G48V/V82A/I84V/L90M. The computed kc and ko
suggest the ﬂaps show a ‘‘slow gating’’ effect, so the gated
association rate constant is simply the ungated rate constant
times the probability of the gate opening (see Eq. 3 and
FIGURE 3 Flap tip distance (GLY51–GLY51) as a function of time in
(top) the wild-type HIV-1 protease and (bottom) variant G48V/V82A/I84V/
L90M.
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reference (14)). As a result, we can predict the gated as-
sociation rate constants for mutant proteases, which are in
reasonable agreements with the experimental data, as shown
in Table 1. The use of a ﬂexible force ﬁeld provides large-
scale internal motions of HIV-1 protease. The calculation is
fast and a 1-ms simulation takes ,2 h CPU time for the
systems studied here. With very modest computational
resources, the method may be applied to estimate the changes
of the association rate constants of different protease mutants
when experimental data are not available, thus provides a
greater understanding of drug-resistance due to protease
mutation.
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